Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.39 +4.8%	$1.96	$1.33 ▼ $3.58	$112.59M	0.74	96,818 shs	193,346 shs
CGC Canopy Growth	$1.27 +2.4%	$1.22	$0.77 ▼ $6.30	$304.61M	0.67	22.15 million shs	17.13 million shs
CTMX CytomX Therapeutics	$2.12 +4.4%	$2.27	$0.40 ▼ $3.10	$349.62M	2.13	3.68 million shs	6.09 million shs
DMAC DiaMedica Therapeutics	$6.11 +3.0%	$4.43	$3.19 ▼ $6.82	$315.82M	1.25	356,804 shs	255,873 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	+41.42%	+20.10%	+31.32%	-5.16%
CGC Canopy Growth	0.00%	-2.31%	+14.41%	-30.60%	-80.16%
CTMX CytomX Therapeutics	0.00%	+10.99%	-11.30%	-4.93%	+66.93%
DMAC DiaMedica Therapeutics	0.00%	+1.33%	+25.20%	+50.49%	+65.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	3.0389 of 5 stars	3.5	5.0	0.0	2.6	1.7	0.0
CGC Canopy Growth	0.7363 of 5 stars	0.0	2.0	0.0	3.3	0.8	1.3
CTMX CytomX Therapeutics	3.8905 of 5 stars	3.5	1.0	4.7	0.6	1.7	1.3
DMAC DiaMedica Therapeutics	1.5386 of 5 stars	3.5	0.0	0.0	2.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	3.00	Buy	$7.00	192.89% Upside
CGC Canopy Growth	1.33	Sell	N/A	N/A
CTMX CytomX Therapeutics	3.00	Buy	$5.75	171.23% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$12.33	101.85% Upside

Current Analyst Ratings Breakdown

Latest ADAG, CTMX, CGC, and DMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/15/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/12/2025	CGC Canopy Growth	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/6/2025	ADAG Adagene	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	ADAG Adagene	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$100K	1,125.93	N/A	N/A	$0.80 per share	2.99
CGC Canopy Growth	$225.65M	1.35	N/A	N/A	$1.47 per share	0.86
CTMX CytomX Therapeutics	$138.10M	2.53	$0.36 per share	5.86	$0.73 per share	2.90
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.53 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$33.42M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	-$429.86M	-$3.03	N/A	N/A	N/A	-155.76%	-89.93%	-44.24%	N/A
CTMX CytomX Therapeutics	$31.87M	$0.56	3.79	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$24.44M	-$0.69	N/A	N/A	N/A	N/A	-78.99%	-69.94%	11/12/2025 (Estimated)

Latest ADAG, CTMX, CGC, and DMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
8/8/2025	Q1 2026	CGC Canopy Growth	-$0.15	-$0.14	+$0.01	-$0.16	$64.98 million	$52.98 million
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	2.29	2.30
CGC Canopy Growth	0.59	3.07	2.12
CTMX CytomX Therapeutics	N/A	4.20	4.20
DMAC DiaMedica Therapeutics	N/A	7.55	7.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
CGC Canopy Growth	3.33%
CTMX CytomX Therapeutics	67.77%
DMAC DiaMedica Therapeutics	10.12%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
CGC Canopy Growth	0.16%
CTMX CytomX Therapeutics	6.60%
DMAC DiaMedica Therapeutics	7.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	37.12 million	Not Optionable
CGC Canopy Growth	3,150	239.85 million	239.47 million	Optionable
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
DMAC DiaMedica Therapeutics	20	51.69 million	47.92 million	Optionable

ADAG, CTMX, CGC, and DMAC Headlines

Recent News About These Companies

DiaMedica Appoints New Chief Medical Officer

August 22 at 8:12 AM | theglobeandmail.com

Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?

August 19, 2025 | zacks.com

DiaMedica Therapeutics' (DMAC) Buy Rating Reiterated at HC Wainwright

August 18, 2025 | americanbankingnews.com

DiaMedica Therapeutics (NASDAQ:DMAC) Receives Buy Rating from HC Wainwright

August 17, 2025 | marketbeat.com

DiaMedica Therapeutics (NASDAQ:DMAC) Announces Quarterly Earnings Results, Hits Estimates

August 14, 2025 | marketbeat.com

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2025 Earnings Call Transcript

August 14, 2025 | insidermonkey.com

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia

August 13, 2025 | seekingalpha.com

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

DiaMedica Therapeutics files $100M mixed securities shelf

August 12, 2025 | msn.com

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 12, 2025 | businesswire.com

Exploring DiaMedica Therapeutics's Earnings Expectations

August 11, 2025 | benzinga.com

Calculating The Fair Value Of DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

August 11, 2025 | finance.yahoo.com

DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.1% - Should You Sell?

August 10, 2025 | marketbeat.com

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

August 6, 2025 | finance.yahoo.com

These 4 Stocks Are Seeing Huge Insider Buying

August 1, 2025 | 247wallst.com

DiaMedica Therapeutics (DMAC) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Insider Buying: DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Major Shareholder Buys 1,542,857 Shares of Stock

July 26, 2025 | marketbeat.com

Jan Stahlberg Acquires 1,542,857 Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Stock

July 26, 2025 | insidertrades.com

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

July 24, 2025 | finance.yahoo.com

DiaMedica Therapeutics raises $30 million in private placement

July 21, 2025 | msn.com

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

July 21, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, CTMX, CGC, and DMAC Company Descriptions

Adagene NASDAQ:ADAG

$2.39 +0.11 (+4.82%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$2.42 +0.02 (+1.05%)

As of 08/22/2025 06:54 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Canopy Growth NASDAQ:CGC

$1.27 +0.03 (+2.42%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.30 +0.03 (+2.76%)

As of 08/22/2025 08:00 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

CytomX Therapeutics NASDAQ:CTMX

$2.12 +0.09 (+4.43%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.10 -0.02 (-0.94%)

As of 08/22/2025 07:42 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

DiaMedica Therapeutics NASDAQ:DMAC

$6.11 +0.18 (+3.04%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.14 +0.03 (+0.56%)

As of 08/22/2025 05:22 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time